Related Experiment Video
Updated: Jul 26, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
Fatih Kus1, Deniz C Guven1, Hasan C Yildirim1
1Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Abstract:
Aim: To assess the prognostic role of the CA-125 elimination rate constant K (KELIM) score in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. Methods: A retrospective study was carried out including 117 patients with advanced-stage platinum-resistant/refractory ovarian cancer treated with liposomal doxorubicin ± bevacizumab. The KELIM score, calculated using CA-125 measurements within the first 100 days of chemotherapy, was used. Survival analyses were performed for overall survival (OS) and progression-free survival (PFS). Results: Higher KELIM scores were associated with a superior PFS and OS. Multivariate analysis confirmed the independent prognostic value of the KELIM score for OS. Validation cohorts showed consistent results. Conclusion: KELIM score may serve as a valuable prognostic marker for predicting OS and PFS in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. Prospective studies are needed for validation.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Cancer Survival Analysis
Kaplan-Meier Approach

